As AML may not depend on BCL-2 for its survival or the dependency may evolve during tumor progression and after therapy[20], a method to assess BCL-2 family dependency is critically needed to predict sensitivity to Venetoclax[4,13,21,22]. The gene discussed is BCL2; the disease is acute myeloid leukemia.